Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The role of allogeneic stem cell transplantation (alloSCT) in multiple myeloma (MM) treatment remains controversial. We conducted a retrospective, multicenter, nationwide study in Korea to evaluate the outcomes of alloSCT in Asian patients with MM. Materials and Methods Overall, 109 patients with MM who underwent alloSCT between 2003 and 2020 were included in this study. Data were collected from the Korean Multiple Myeloma Working Party Registry. Results The overall response rate and stringent complete response plus complete response (CR) rates were 67.0 and 46.8%, respectively, after alloSCT. At a median follow-up of 32.5 months, the 3-year probability of progression-free survival (PFS) and overall survival (OS) rates were 69.3% and 71.8%, respectively. The 3-year probabilities of OS rates in the upfront alloSCT, tandem auto-alloSCT, and later alloSCT groups were 75.0%, 88.9%, and 61.1%, respectively. Patients who achieved CR before or after alloSCT had significantly longer OS (89.8 vs. 18 months and 89.8 vs. 15.2 months, respectively). Even though patients who did not achieve CR prior to alloSCT, those who achieve CR after alloSCT had improved PFS and OS compared to those who had no achievement of CR both prior and after alloSCT. Patients who underwent alloSCT with 1-2 prior treatment lines had improved PFS (22.4 vs. 4.5 months) and OS (45.6 vs. 15.3 months) compared to those with three or more prior treatment lines. Conclusion AlloSCT may be a promising therapeutic option especially for younger, chemosensitive patients with earlier implementation from relapse.
Abstract
Purpose The role of allogeneic stem cell transplantation (alloSCT) in multiple myeloma (MM) treatment remains controversial. We conducted a retrospective, multicenter, nationwide study in Korea to evaluate the outcomes of alloSCT in Asian patients with MM. Materials and Methods Overall, 109 patients with MM who underwent alloSCT between 2003 and 2020 were included in this study. Data were collected from the Korean Multiple Myeloma Working Party Registry. Results The overall response rate and stringent complete response plus complete response (CR) rates were 67.0 and 46.8%, respectively, after alloSCT. At a median follow-up of 32.5 months, the 3-year probability of progression-free survival (PFS) and overall survival (OS) rates were 69.3% and 71.8%, respectively. The 3-year probabilities of OS rates in the upfront alloSCT, tandem auto-alloSCT, and later alloSCT groups were 75.0%, 88.9%, and 61.1%, respectively. Patients who achieved CR before or after alloSCT had significantly longer OS (89.8 vs. 18 months and 89.8 vs. 15.2 months, respectively). Even though patients who did not achieve CR prior to alloSCT, those who achieve CR after alloSCT had improved PFS and OS compared to those who had no achievement of CR both prior and after alloSCT. Patients who underwent alloSCT with 1-2 prior treatment lines had improved PFS (22.4 vs. 4.5 months) and OS (45.6 vs. 15.3 months) compared to those with three or more prior treatment lines. Conclusion AlloSCT may be a promising therapeutic option especially for younger, chemosensitive patients with earlier implementation from relapse.
참고문헌 (28)
- Kumar SK, "Improved survival in multiple myeloma and the impact of novel therapies", Blood, 111, pp.2516~2520 (2008)
- Palumbo A, "Multiple myeloma", N Engl J Med, 364, pp.1046~1060 (2011)
- Katodritou E, "Is it possible to cure myeloma without allogeneic transplantation?", Transfus Apher Sci, 54, pp.63~70 (2016)
- Lokhorst H, "International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma", J Clin Oncol, 28, pp.4521~4530 (2010)
- Barlogie B, "Treatment of multiple myeloma", Blood, 103, pp.20~32 (2004)
- Kim HT, "Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies : the cost of freedom", Biol Blood Marrow Transplant, 19, pp.860~866 (2013)
- Giralt S, "American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma", Biol Blood Marrow Transplant, 21, pp.2039~2051 (2015)
- Gahrton G, "Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma : a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres", Br J Haematol, 113, pp.209~216 (2001)
- Glucksberg H, "Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors", Transplantation, 18, pp.295~304 (1974)
- Durie BG, "International uniform response criteria for multiple myeloma", Leukemia, 20, pp.1467~1473 (2006)
- Scott EC, "Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma : a CIBMTR analysis", Biol Blood Marrow Transplant, 22, pp.1893~1899 (2016)
- Iacobelli S, "Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma : results from the EBMT NMAM2000 prospective trial", Bone Marrow Transplant, 50, pp.505~510 (2015)
- Ocio EM, "New drugs and novel mechanisms of action in multiple myeloma in 2013 : a report from the International Myeloma Working Group(IMWG)", Leukemia, 28, pp.525~542 (2014)
- Qazilbash MH, "Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma", Cancer, 106, pp.1084~1089 (2006)
- Auner HW, "Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation : a study by the European Group for Blood and Marrow Transplantation", Bone Marrow Transplant, 48, pp.1395~1400 (2013)
- Freytes CO, "Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation", Bone Marrow Trans-plant, 49, pp.416~421 (2014)
- Patriarca F, "Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft : a multicenter retrospective study based on donor availability", Biol Blood Marrow Transplant, 18, pp.617~626 (2012)
- de Lavallade H, "Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma", Bone Marrow Transplant, 41, pp.953~960 (2008)
- Rotta M, "Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting", Blood, 113, pp.3383~3391 (2009)
- Rosinol L, "A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma", Blood, 112, pp.3591~3593 (2008)
- Crawley C, "Outcomes of reduced-intensity transplantation for chronic myeloid leukemia : an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT", Blood, 106, pp.2969~2976 (2005)
- Kim I, "Allogeneic stem cell transplantation for patients with advanced hematological malignancies : comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning", J Korean Med Sci, 22, pp.227~234 (2007)
- Kawamura K, "The role of allogeneic transplantation for multiple myeloma in the era of novel agents : a study from the Japanese Society of Myeloma", Biol Blood Marrow Transplant, 24, pp.1392~1398 (2018)
- Montefusco V, "Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients", Bone Marrow Transplantation, 52, pp.1602~1608 (2017)
- Khaled Y, "Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect", Bone Marrow Transplant, 44, pp.325~326 (2009)
- Kuruvilla J, "Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma", Biol Blood Marrow Transplant, 13, pp.925~931 (2007)
- Gahrton G, "Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma", Haematologica, 92, pp.1513~1518 (2007)
- Bashir Q, "A randomized phase II trial of fludarabine", melphalan 100 versus fludarabine, Biol Blood Marrow Transplant, pp.2013, 19[DOI]